1,3,5-Triazin-2-yl Phosphoramidates for Sofosbuvir Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing sofosbuvir, a nucleotide inhibitor for hepatitis C, face challenges in achieving high yields and purity of the Sp diastereoisomer due to limitations in regioselective substitution and purification processes, particularly with aryloxy leaving groups.
Innovation Solution
The use of 1,3,5-triazin-2-yl phosphoramidates with specific substituents allows for improved regioselective substitution and increased yields, enabling easier purification by exploiting differences in solubility between hydrophilic and lipophilic triazine derivatives, facilitating extraction and crystallization processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If aryloxy leaving groups (e.g., 4-nitrophenoxy, pentafluorophenoxy) are used in phosphoramidate precursors, then the Sp diastereoisomer can be obtained by crystallization, but the total yield remains low (37-53%) and purification requires multiple steps including resolution or chromatography
Solution Approach 1:
The invention changes the chemical structure parameter of the leaving group from traditional aryloxy groups (4-nitrophenoxy, pentafluorophenoxy) to 1,3,5-triazin-2-yl phosphoramidates with specific substituents (R1 = H, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl). This structural parameter change fundamentally alters the properties of the leaving group, enabling both high optical purity (>99% de) and high total yield (>50%) of the Sp diastereoisomer through a single crystallization step, eliminating the need for resolution or chromatography.
2Manufacturing precision
If traditional aryloxy leaving groups are used, then crystallization can provide diastereomeric enrichment, but additional purification steps (resolution, chromatography) are required to achieve diastereomerically pure product
Solution Approach 1:
The invention extracts the problematic purification steps (resolution, chromatography) from the synthetic pathway by designing a leaving group (1,3,5-triazin-2-yl phosphoramidate) that enables direct crystallization to diastereomeric purity. The specific substituent patterns on the triazine ring (R1 = H, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl) are chosen to optimize crystallization behavior, allowing the Sp diastereoisomer to be obtained in >99% de in a single step, thereby removing unnecessary purification operations.
3Reliability
If conventional leaving groups are used, then the reaction proceeds through SN2 mechanism with inversion of configuration, but the process requires equimolar (1:1) mixture of diastereoisomers that must be separated by resolution or chromatography
Solution Approach 1:
The invention changes the leaving group parameter from conventional aryloxy groups to 1,3,5-triazin-2-yl phosphoramidates with specific substituents. This parameter change maintains the stereospecific SN2 reaction mechanism with inversion of configuration at the chiral phosphorus atom, but simultaneously enables the crude reaction mixture (containing Sp:Rp 1:1 mixture) to be directly converted to diastereomerically pure Sp product through crystallization, achieving >50% total yield without requiring separation of the equimolar mixture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in higher yields (>50%) and excellent optical purity (>99%) of the Sp diastereoisomer, providing a more efficient and cost-effective method for producing sofosbuvir while offering a 'green' alternative to traditional phenolic derivative-based methods.
Implementation Method 1
The reaction runs stereospecifically through the so-called SN2 mechanism with inversion of the configuration at the chiral phosphorus atom
Implementation Method 2
The respective Sp diastereoisomer can be obtained by crystallization
Implementation Method 3
enabling easier purification by exploiting differences in solubility between hydrophilic and lipophilic triazine derivatives, facilitating extraction and crystallization processes
Data Source
AI summary
The present invention relates to a new type of 1,3.5-triazin-2-yl phosphoramidates of general formula I with the absolute configuration (S) at the phosphorus atom, an Sp diastereoisomer, wherein R1 and R2 can independently be H, a C1-C6 (un)branched alkyl, a C1-C6 (un)branched alkoxy group, a C1-C6 (un)branched alkylsulfanyl group, C1-C6 (un)branched monoalkylamino or dialkylamino group, including cyclic amino groups, e.g. pyrrolidino, piperidino or morpholino group; and to their use for the production of biologically active phosphoramidate prodrugs, especially sofosbuvir of formula II. Sofosbuvir II is a nucleotide inhibitor of the RNA polymerase, used for the treatment of hepatitis C in the form of a prodrug, releasing the active antiviral agent 2'-deoxy-2'-a-fluoro- P-C-methyluridine-5'-triphosphate in the organism.